Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05485207 · ClinicalTrials.gov registry record · Early Phase 1

Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome

A Early Phase 1 study of Interstitial Cystitis and Bladder Pain Syndrome, sponsored by Stanford University.

Active
Registry status
Early Phase 1
Development phase
5
Enrollment target
1
Study location

NCT05485207 is a Early Phase 1 study of Interstitial Cystitis and Bladder Pain Syndrome that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 5 participants, below the 362-participant average among 26 other Interstitial Cystitis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05485207, a Early Phase 1 study of Interstitial Cystitis and Bladder Pain Syndrome, is active but no longer recruiting, sponsored by Stanford University.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
5 participants
Enrollment target
1
Study location

Study Summary

Interstitial cystitis / bladder pain syndrome (IC/BPS) is a debilitating condition that affects millions of women in the United States. Women suffer from recurring pelvic pain, bladder pressure, painful bladder, urinary frequency (needing to go often) and urgency (feeling a strong need to go). Women are five times more likely to suffer from IC/BPS than men. IC/BPS is a common cause of painful bladder after excluding urinary tract infection. About one-third of women resort to opioids, thus contributing to the current opioid crisis. Sadly, there are no durable treatments and the majority of therapies are not FDA-approved for IC/BPS.

Conditions Studied

Interstitial Cystitis Bladder Pain Syndrome

Interventions

  • DRUG Transvaginal botulinum toxin A (BTA) injection

Study Locations (1)

California

  • Urology Clinic (Stanford University), 1000 Welch Road, Suite 100 - Palo Alto

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2022-04-04
Est. Completion 2025-02-28
Phase Early Phase 1

Sponsor

Stanford University

1,744 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05485207

The ClinicalTrials.gov registry entry for NCT05485207 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 362-participant average among 26 other Interstitial Cystitis trials with a reported enrollment target (99% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Interstitial Cystitis appearing as the primary indexed condition, and to 1 intervention - of which Transvaginal botulinum toxin A (BTA) injection is the first listed.

NCT05485207 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05485207 about?

NCT05485207 is a clinical study titled "Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome". Interstitial cystitis / bladder pain syndrome (IC/BPS) is a debilitating condition that affects millions of women in the United States. Women suffer from recurring pelvic pain, bladder pressure, painful bladder, urinary frequency (needing to go often) and urgency (feeling a strong need to go). Women...

What is the current status of trial NCT05485207?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2022-04-04. Estimated completion is 2025-02-28.

What conditions does trial NCT05485207 study?

This clinical trial studies the following conditions: Interstitial Cystitis, Bladder Pain Syndrome.

What interventions are being tested in trial NCT05485207?

The interventions under investigation include: Transvaginal botulinum toxin A (BTA) injection (DRUG).

Who is sponsoring clinical trial NCT05485207?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05485207 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Interstitial Cystitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Interstitial Cystitis

All registered trials for this condition

Bladder Pain Syndrome

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.